Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809327 | 1.00 | TLR7 (0.47) | TLR7ADORA2AADORA2BTLR8 | |
| SCHEMBL2486847 | 0.99 | TLR7 (0.47) | TLR7ADORA2AADORA2BTLR8 | |
| SCHEMBL2200726 | 0.90 | TLR7 (0.41) | TLR7ADORA2AADORA2B | |
| SCHEMBL10057869 | 0.90 | ADORA2A (0.37) | TLR7ADORA2AADORA2B | |
| SCHEMBL2199084 | 0.89 | TLR7 (0.37) | TLR7ADORA2AADORA2B | |
| SCHEMBL31124759 | 0.89 | ADORA2A (0.40) | TLR7ADORA2AADORA2B | |
| SCHEMBL2199802 | 0.88 | ADORA2A (0.43) | TLR7ADORA2AADORA2B | |
| SCHEMBL24733095 | 0.88 | TLR7 (0.49) | TLR7 | |
| SCHEMBL2199990 | 0.87 | ADORA2A (0.42) | TLR7ADORA2AADORA2B | |
| SCHEMBL31126573 | 0.87 | TLR7 (0.38) | TLR7ADORA2AADORA2BTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562011-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | Zymeworks BC Inc. (CA) | 2025-06-04 | — | — | EP | disclosed |
| US-20250170266-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2025-05-29 | — | — | US | disclosed |
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| WO-2024020684-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2024-02-01 | — | — | WO | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114805341-A | Aromatic heterocyclic compounds and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG A CORPORATION OF SWEDEN (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939200-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1728793-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TLR7 612/4885ADORA2A 2/4885ADORA2B 6/4885 |
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | TLR7 1/4885ADORA2A 333/4885ADORA2B 429/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | TLR7 8/4885ADORA2A 83/4885ADORA2B 99/4885 |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885ADORA2A 78/4885ADORA2B 46/4885 |
| US-20080300244-A1 | NOVEL COMPOUNDS | NPY1R, F12, NPY2R | TLR7 3711/4885ADORA2A 133/4885ADORA2B 49/4885 |
| US-20090099216-A1 | NOVEL ADENINE COMPOUND | ADORA1, CXCR6, NR0B1 | TLR7 490/4885ADORA2A 11/4885ADORA2B 60/4885 |
| US-20250170266-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | PAICS, ENTPD5, PNP | TLR7 279/4885ADORA2A 5/4885ADORA2B 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.